Design, Development and Evaluation of Pulsatile Drug Delivery System of Eprosartan Mesylate for Chronopharmacotheraphy
نویسنده
چکیده
INTRODUCTION Pulsatile Drug delivery systems are gaining a lot of interest as they deliver the drug at the right site of action at the right time and in the right amount, thus providing spatial and temporal delivery and increasing patient compliance. Pulsatile Drug Delivery systems are basically time-controlled drug delivery systems in which the system controls the lag time independent of environmental factors like pH, ABSTRACT The chronopharmacotherapy drug delivery system is widely used for treatment of diseases occurs due to circadian changes in the body. This system is aims to release drugs at a programmed pattern i.e.at appropriate time and/or at appropriate site of action. In this investigation, a novel oral pulsatile drug delivery system based on a core-in-cup dry coated tablet, where a core tablet surrounded on the bottom and circumference wall with inactive material. The system consists of three parts, a core tablet, containing the active ingredient, an impermeable outer shell and top cover layer of hydrophilic polymer. The core containing Eprosartan Mesylate as a bioactive compound was prepared by direct compression method and evaluated for thickness, hardness, weight variation and friability. The impermeable coating cup consisted of hydrophobic polymer of cellulose acetate propionate, and the top cover layer of hydrophilic swellable materials (Sodium Alginate, HPMC K4M, Sodium carboxy methylcellulose,) were used in different concentration. The tablets prepared were evaluated for Micromeritic properties, hardness, thickness, weight variation, friability, drug content uniformity and in-vitro drug release study. The drug-excipients study was carried out by using FT-IR. From the obtained results, it was found that the order of sustaining capacity of pulsatile device is, HPMC K4M > Sodium CMC > Sodium alginate.
منابع مشابه
Design, Evaluation and Comparative Study of Pulsatile Release from Tablet and Capsule Dosage Forms
The objective of present research was to design, evaluate and compare drug release from two different dosage forms in pulsatile drug delivery system (DDS) for Metoprolol tartarate (MT) as tablet and capsule. Pulsatile systems are gaining a lot of interest as they deliver the drug at the right site of action at the right time and in the right amount, thus providing spatial and temporal del...
متن کاملSolid Sirolimus Self-microemulsifying Drug Delivery System: Development and Evaluation of Tablets with Sustained Release Property
The clinical application of sirolimus (SRL) as an immunosuppressive agent is largely hampered by its narrow therapeutic range. This study focused on developing SRL tablets with a sustained release profile for better safety. SRL was highly water insoluble and its solubility has been efficiently enhanced by preparing self-microemulsifying drug delivery system (SMEDDS). The SRL-SMEDDS was physical...
متن کاملSolid Sirolimus Self-microemulsifying Drug Delivery System: Development and Evaluation of Tablets with Sustained Release Property
The clinical application of sirolimus (SRL) as an immunosuppressive agent is largely hampered by its narrow therapeutic range. This study focused on developing SRL tablets with a sustained release profile for better safety. SRL was highly water insoluble and its solubility has been efficiently enhanced by preparing self-microemulsifying drug delivery system (SMEDDS). The SRL-SMEDDS was physical...
متن کاملDevelopment and Validation of a UV Spectrophotometric Method for the Simultaneous Estimation of Eprosartan Mesylate and Hydrochlorothiazide in Bulk and Formulations
A simple, efficient, precise and accurate absorbance ratio method have been developed for the estimation of eprosartan mesylate and hydrochlorothiazide in pure and in fixed dose combination. In this method, UV spectra of eprosartan mesylate and hydrochlorothiazide were overlayed which involves the formation of Q-absorbance equation at 249.1 nm (isobestic point) and 274.5 nm, the max of hydrochl...
متن کاملTEVETEN HCT (eprosartan mesylate/hydrochlorothiazide) 600/12.5mg 600/25mg Rx Only PRESCRIBING INFORMATION WARNING: FETAL TOXICITY
DESCRIPTION TEVETEN HCT 600/12.5 mg and TEVETEN HCT 600/25 mg (eprosartan mesylate hydrochlorothiazide) combine an angiotensin II receptor (AT1 subtype) antagonist and a diuretic, hydrochlorothiazide. TEVETEN (eprosartan mesylate) is a non-biphenyl non-tetrazole angiotensin II receptor (AT1) antagonist. A selective non-peptide molecule, TEVETEN is chemically described as the monomethanesulfona...
متن کامل